



European Medicines Agency
Evaluation of Medicines for Human Use

London, 27 July 2006
Doc. Ref. EMEA/CHMP/VWP/244894/2006

COMMITTEE FOR HUMAN MEDICAL PRODUCTS (CHMP)
--

EXPLANATORY NOTE ON IMMUNOMODULATORS FOR THE GUIDELINE ON ADJUVANTS IN VACCINES FOR HUMAN USE
--

AGREED BY VACCINE WORKING PARTY	06 July 2006
ADOPTION BY CHMP	27 July 2006

KEYWORDS	Immunomodulators, adjuvants, vaccines
----------	---------------------------------------

The current version of the “*Note for guidance on adjuvants in vaccines for human use*” (EMA/CHMP/VEG/134716/2004) lists compounds such as MF 59 and GM-CSF, as examples of adjuvants (footnote 2 of the guideline, p. 6/18). However, such products can also be administered separately and/or at a different time point from the vaccine antigen, in order to pre-condition the immune system, where both molecules are needed for vaccine activity.

According to Directive 2001/83/EC, an adjuvant is a constituent of the medicinal product. This is also reflected in the introduction of the Guideline on adjuvants in vaccines for human use, where it is stated that “*incorporation of adjuvants into vaccine formulations is aimed at enhancing, accelerating and prolonging the specific immune response towards the desired response to vaccine antigens*”. Hence, it is concluded that an adjuvant should be part of the (reconstituted) formulation that is administered. Compounds that are given separately and/or at a different time point are therefore not considered to be adjuvants and are called immunomodulators.

An adjuvant is intended to help the immune response by a local, simultaneous and concomitant action with the antigen. Immunomodulators pre-condition the immune system in a more systemic way.

Nevertheless, most of the principles of the Guideline on adjuvants in vaccines for human use are also applicable to immunomodulators.